CGEN.TA - Compugen Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
1,058.00
-51.00 (-4.60%)
At close: 5:24PM IST
Stock chart is not supported by your current browser
Previous Close1,109.00
Open1,109.00
Bid1,049.00 x 1500
Ask1,050.00 x 200
Day's Range1,050.00 - 1,096.00
52 Week Range839.00 - 1,636.00
Volume40,981
Avg. Volume27,851
Market Cap571.131M
Beta (3Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)-0.42
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Thomson Reuters StreetEvents13 days ago

    Edited Transcript of CGEN.TA earnings conference call or presentation 7-Nov-18 1:15pm GMT

    Q3 2018 Compugen Ltd Earnings Call

  • PR Newswirelast month

    Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy

    HOLON, Israel, Nov. 13, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that a patent for COM902, the Company's TIGIT therapeutic antibody candidate, has been issued by the United States Patent and Trademark Office (USPTO) under the USPTO's Cancer Moonshot Pilot Program providing early examination of patent applications pertaining to cancer immunotherapy. Activating T cells results in stimulating the immune system, and therefore could be used for cancer immunotherapy treatment. This patent as well as other patents the Company is pursuing for COM902 are part of its global patent strategy covering its innovative immuno-oncology pipeline.

  • Compugen (CGEN) Reports Q3 Loss
    Zackslast month

    Compugen (CGEN) Reports Q3 Loss

    Compugen (CGEN) delivered earnings and revenue surprises of 58.33% and 0.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Compugen: 3Q Earnings Snapshot

    The Holon, Israel-based company said it had a loss of 5 cents per share. The drug developer posted revenue of $7.8 million in the period. The company's shares closed at $3.08. A year ago, they were trading ...

  • PR Newswirelast month

    Compugen Reports Third Quarter 2018 Results

    HOLON, Israel , Nov. 7, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for ...

  • Compugen Ltd. (CGEN) Sees Hammer Chart Pattern: Time to Buy?
    Zackslast month

    Compugen Ltd. (CGEN) Sees Hammer Chart Pattern: Time to Buy?

    Compugen has been struggling lately, but the selling pressure may be coming to an end soon.

  • PR Newswire2 months ago

    Compugen Third Quarter 2018 Conference Call Scheduled for Wednesday, November 7, 2018 at 8:30 AM ET

    HOLON, Israel , Oct. 24, 2018 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company ...

  • Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
    Zacks2 months ago

    Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal

    AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.

  • Bristol-Myers Inks Deal and Invests $12 Million in Compugen
    Zacks2 months ago

    Bristol-Myers Inks Deal and Invests $12 Million in Compugen

    Bristol-Myers (BMY) enters a clinical trial collaboration with Compugen and will make a $12-million equity investment in the latter.

  • Reuters2 months ago

    Bristol-Myers to invest in Compugen, collaborate in clinical trials

    Bristol-Myers Squibb Co and Israel's Compugen said on Thursday they will collaborate in clinical trials for patients with advanced solid tumours. The trials will evaluate the safety and tolerability of Compugen’s COM701, an investigational antibody, in combination with Bristol-Myers Squibb’s immune checkpoint inhibitor Opdivo. In conjunction with the collaboration, Bristol-Myers Squibb will invest $12 million in Compugen, purchasing 2,424,243 shares - equal to a 4.1 percent stake - at $4.95 each.

  • PR Newswire2 months ago

    Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors

    NEW YORK and HOLON, Israel , Oct. 11, 2018 /PRNewswire/ --  Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration ...

  • PR Newswire3 months ago

    Compugen Announces Clinical Milestone Payment in Cancer Immunotherapy Collaboration With Bayer Following Dosing of First Patient in BAY 1905254 Phase 1 Trial

    HOLON, Israel, Sept. 20, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, was informed that Bayer AG dosed the first patient in the Phase 1 clinical trial of BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting the ILDR2 protein, in patients with advanced solid tumors.  Under the terms of the collaboration and license agreement, Compugen is entitled to a milestone payment of $7.8 million at first patient dosing.

  • Should You Have Compugen Ltd’s (NASDAQ:CGEN) In Your Portfolio?
    Simply Wall St.3 months ago

    Should You Have Compugen Ltd’s (NASDAQ:CGEN) In Your Portfolio?

    Anyone researching Compugen Ltd (NASDAQ:CGEN) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there areRead More...

  • PR Newswire3 months ago

    Compugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial

    HOLON, Israel, Sept. 7, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in its Phase 1 clinical trial of COM701, a first-in-class cancer immunotherapy antibody targeting PVRIG. PVRIG is a novel immune checkpoint identified by Compugen using its computational discovery capabilities. "Dosing the first patient with COM701, a first-in-class drug opportunity targeting a novel immune checkpoint we identified with our computational predictive platform, is a landmark event for us.

  • PR Newswire3 months ago

    Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors

    HOLON, Israel, Sept. 5, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the appointment of Jean-Pierre Bizzari, M.D., formerly Executive Vice President and Global Head of Oncology at Celgene Corporation, to its Board of Directors. "I am delighted to welcome Jean-Pierre to Compugen's Board," said Paul Sekhri, Chairman of the Board. "I am confident that his extensive experience in oncology drug development will prove invaluable to Compugen.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CGEN.TA earnings conference call or presentation 1-Aug-18 12:30pm GMT

    Q2 2018 Compugen Ltd Earnings Call

  • Associated Press5 months ago

    Compugen: 2Q Earnings Snapshot

    The Holon, Israel-based company said it had a loss of 19 cents per share. The company's shares closed at $3.15. A year ago, they were trading at $4.05. _____ This story was generated by Automated Insights ...

  • PR Newswire5 months ago

    Compugen Reports Second Quarter 2018 Results

    Preparations for first patient dosing on track to take place in early fall HOLON, ISRAEL , Aug 1, 2018 /PRNewswire/ -- Compugen Ltd. ( Nasdaq: CGEN ), a clinical-stage cancer immunotherapy company and ...

  • PR Newswire5 months ago

    Compugen Second Quarter 2018 Conference Call Scheduled for Wednesday, August 1, 2018 at 8:30 AM ET

    HOLON, Israel , July 18, 2018 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company ...

  • Benzinga6 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Alkermes Plc (NASDAQ: ALKS ) stock was trading higher ...

  • PR Newswire6 months ago

    Compugen Welcomes FDA Clearance of Bayer's IND Application for BAY 1905254

    HOLON, Israel, July 2, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN) (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, was informed that the U.S. Food and Drug Administration (FDA) has cleared Bayer AG's investigational new drug (IND) application for BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting the ILDR2 protein in patients with advanced solid tumors. ILDR2 is a novel immune checkpoint discovered by Compugen through its predictive computational capabilities, which enable the discovery of new drug targets and biological pathways.

  • When Should You Buy Compugen Ltd (NASDAQ:CGEN)?
    Simply Wall St.6 months ago

    When Should You Buy Compugen Ltd (NASDAQ:CGEN)?

    Compugen Ltd (NASDAQ:CGEN), a life sciences company based in Israel, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqGM. Less-covered, smallRead More...

  • PR Newswire6 months ago

    Compugen Announces the Appointment of New Board Members

    HOLON, Israel, June 11, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the appointment of three new members to its Board of Directors. Mr. Gilead Halevy, founding member and general partner of Kedma Capital Partners, Kinneret Livnat Savitzky, Ph.D., Interim CEO and board member of FutuRx Ltd., and Mr. Sanford (Sandy) Zweifach, founder and CEO of Nuvelution Pharma, Inc. were appointed to Compugen's Board.

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of CGEN.TA earnings conference call or presentation 9-May-18 1:45pm GMT

    Q1 2018 Compugen Ltd Earnings Call

  • Market Has Not Yet Noticed Potential in Compugen; Have You?
    Zacks7 months ago

    Market Has Not Yet Noticed Potential in Compugen; Have You?

    Compugen (CGEN) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.